JointHealth™ express   March 7, 2023

Let BC PharmaCare hear "Your Voice" on upadacitinib (Rinvoq™) for the treatment of ankylosing spondylitis .

Upadacitinib (Rinvoq™) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about upadacitinib for the treatment of ankylosing spondylitis.

You can give input if you are a B.C. resident and have ankylosing spondylitis, a caregiver to someone with ankylosing spondylitis, or if your group represents people who live with ankylosing spondylitis.

If you would like our help in providing your input, you can email your comments to or call us at 604-974-1366. Your feedback will be anonymized and collated with others who choose to provide it to ACE for submission on their behalf. Please provide your input to us by Friday, March 24 so that we may submit the questionnaire in time for the deadline.

The submission deadline is March 29, 2023. Patients and caregivers may give their input directly through the link below.

Please click on information sheet link below to learn more about upadacitinib and the questionnaire link below to let BC PharmaCare hear Your Voice:

  • To view the information sheet for updacitinib for the treatment of ankylosing spondylitis: click here
  • To complete the Questionnaire as a patient, caregiver, or patient group representative: click here